European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?

European Urology, Supplements

Volumn 7, Issue 2, 2008, Pages 46-54

  Patard, Jean Jacques ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Guidelines; PDGF; Renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapy; Temsirolimus; VEGF; VHL

Indexed keywords

ALPHA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1; PLACEBO; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ALOPECIA; ANEMIA; ASTHENIA; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HEALTH CARE ORGANIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UROLOGY;

EID: 38549124312     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.12.002     Document Type: Review

References (27)

1. Ljungberg B., Hanbury D.C., Kuczyk M.A., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
2. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
3. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
4. Tsuchiya N., Sato K., Akao T., et al. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohoku J Exp Med 195 (2001) 101-113
5. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
6. Wiesener M.S., Münchenhagen P.M., Berger I., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 61 (2001) 5215-5222
7. Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275 (2000) 25733-25741
8. Iliopoulos O., Levy A.P., Jiang C., Kaelin Jr. W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93 (1996) 10595-10599
9. Berger D.P., Herbstritt L., Dengler W.A., et al. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 6 (1995) 817-825
10. Bellmunt J. Current treatment in advanced renal cell carcinoma (RCC): impact of targeted therapies in the management of RCC. Eur J Cancer Suppl 6 (2007) 484-491
11. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
12. Sulzbacher I., Birner P., Träxler M., Marberger M., and Haitel A. Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120 (2003) 107-112
13. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
14. Pfizer Inc. Sutinib malate: summary of product characteristics. 2006.
15. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
16. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
17. Motzer RJ, Figlin TE, Hutson P, et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. American Society of Clinical Oncology Meeting Abstracts 2007;25:5024.
18. Rosenberg JE, Motzer JR, Michaelson BG, et al. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival. American Society of Clinical Oncology Meeting Abstracts 2007;25:5095.
19. Escudier B., Chevreau C., Lasset C., et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol 17 (1999) 2039-2043
20. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
21. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
22. Bayer Healthcare AG. Nexavar summary of product characteristics. 2006.
23. Bayer Healthcare AG. Nexavar US prescribing information. 2007.
24. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
25. Skotnicki J.S., Leone C.L., Smith A.L., et al. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin Cancer Res 7 (2001) 3749s-3750s
26. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
27. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281